NCT05798117已完成1 期
An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Participants With Severe, Refractory Systemic Lupus Erythematosus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 11
- 主要终点
- Number of participants with AEs and SAEs
研究概览
简要总结
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Adequate renal, hepatic, cardiac, hematological and pulmonary function
- •Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE.
- •Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of ≥1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN)
- •Active (severe) disease as defined by SLEDAI-2K ≥ 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements:
- •At least moderate or severe peri/myocarditis
- •At least moderate or severe pleuritis or other lung involvement
- •Vasculitis
- •Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country).
排除标准
- •Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening.
- •Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy
- •Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis
- •Any patients requiring medications prohibited by the protocol
- •Any psychiatric condition or disability making compliance with treatment or informed consent impossible
- •Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy)
- •History of bone marrow/hematopoietic stem cell or solid organ transplantation
- •Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study
- •Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion (or longer if required as per local regulations) and until CAR-T cells are no longer present by qPCR on two consecutive tests
- •Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests
- •Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome
- •Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient
- •B cell aplasia
研究组 & 干预措施
YTB323
Experimental
Single infusion of YTB323
干预措施: YTB323 (Drug)
结局指标
主要结局
Number of participants with AEs and SAEs
时间窗: Day 1 to 2 years
Long term safety follow up
次要结局
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax)(Pre-dose, up to 2 years)
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC)(Pre-dose, up to 2 years)
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax)(Pre-dose, up to 2 years)
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2)(Pre-dose, up to 2 years)
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast)(Pre-dose, up to 2 years)
- CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast)(Pre-dose, up to 2 years)
- Number of patients with anti-drug antibodies(Pre-dose, up to 2 years)
- Level of T cell activation by YTB323(Pre-dose, up to 2 years)
- Number of patients infused with planned target dose(Day 1)
- Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score(Pre-dose, up to 2 years)
- Change from pre-dose up to 2 years in Physician's global assessment (PGA)(Pre-dose, up to 2 years)
- Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS)(Pre-dose, up to 2 years)
- Remission rate(Up to 2 years)
- Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR)(Pre-dose, up to 2 years)
- Incidence of Complete renal response (CRR)(Up to 2 years)
研究者
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
1 期
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06704269Novartis Pharmaceuticals15
已完成
3 期
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerBreast CancerNCT02019277Hoffmann-La Roche50
已完成
3 期
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyPrimary Immune DeficiencyNCT00419341CSL Behring49
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
撤回
3 期
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaVentilator-Associated PneumoniaHospital-Acquired Bacterial PneumoniaHospital-Acquired PneumoniaVentilator-Associated Bacterial PneumoniaNCT03006679Melinta Therapeutics, Inc.